Hepatitis C Virus in the Modern Direct‐Acting Antiviral Era: Where Have All the Special Populations Gone?

Ramers, Christian B.; Trooskin, Stacey

doi:10.1002/cld.786

Cited by 1 publication

(1 citation statement)

References 43 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, reduces the risk of cardiovascular disease, diabetes and extra-hepatic cancers and improves their quality of life [17] . The access to new DAAs that mainly metabolized in the liver with minimal renal elimination as the ombitasvir,, and ritonavir-boosted paritaprevir [OBV/PTV/RTV] is available in a fixeddose combination pill [18] . This combination is requiring no dose adjustment in patients with renal impairment.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Ombitasvir/Paritaprevir/Ritonavir plus Ribavirin in Treatment of Chronic Hepatitis C Patients with End Stage Renal Disease on Regular Hemodialysis

Elgendy

El-Raey

Nassib

et al. 2020

International Journal of Medical Arts

View full text Add to dashboard Cite

Background: Hepatitis C virus [HCV] infection is associated with more significant morbidity and mortality among dialysis patients than in healthy populations. The fixed-dose tablet [ombitasvir/ paritaprevir/ritonavir] in combination with ribavirin was effective and generally well tolerated in treatment of chronic HCV infected patients with end stage renal disease [ESRD] on hemodialysis. However, limited published data are known about the usefulness of this regimen for treatment of HCV patients with ESRD on hemodialysis. Aim of the work: The aim of this study was to evaluate the safety and efficacy of treatment regimen of ombitasvir [OBV] 25 mg /paritaprevir [PTV] 150 mg /ritonavir [RTV] 100 mg plus generic ribavirin [RBV] 200 mg in Egyptian HCV-infected naive patients with ESRD on regular hemodialysis. Patients and methods: A prospective cohort study involved 40 chronic HCV on regular hemodialysis patients, who were eligible for treatment with combined oral antiviral therapy. Results: The results showed that thirty-five patients [35/40[87.5%]] completed 12 weeks of HCV therapy; they had a virological response at end of therapy and sustained virological response. Anemia was the main observed side effect which lead to discontinuation of the treatment in five patients [12.2%]. As these patients were not responding to anemia correction measures [blood transfusion, erythropoietin-stimulating agents, and modification of RBV dose]. Conclusion: OBV/PTV/RTV plus Ribavirin can be used in treatment of chronic HCV patients with ESRD on regular hemodialysis. This is an open access article under the Creative Commons license [CC BY] [https://creativecommons.org/licenses/by/2.0/] Please cite this article as El-Gendy NA, EL-Raey FM, Nassibi SA, Elsadany N. Efficacy of Ombitasvir/Paritaprevir/Ritonavir plus Ribavirin in Treatment of Chronic Hepatitis C Patients with End Stage Renal Disease on Regular Hemodialysis. IJMA 2020; 2[1]: 313-319.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of Ombitasvir/Paritaprevir/Ritonavir plus Ribavirin in Treatment of Chronic Hepatitis C Patients with End Stage Renal Disease on Regular Hemodialysis

Elgendy

El-Raey

Nassib

et al. 2020

International Journal of Medical Arts

View full text Add to dashboard Cite

show abstract

Hepatitis C Virus in the Modern Direct‐Acting Antiviral Era: Where Have All the Special Populations Gone?

Abstract: http://aasldpubs.onlinelibrary.wiley.com/hub/journal/10.1002/(ISSN)2046-2484/video/12-5-reading-ramers a video presentation of this article

Cited by 1 publication

References 43 publications

Efficacy of Ombitasvir/Paritaprevir/Ritonavir plus Ribavirin in Treatment of Chronic Hepatitis C Patients with End Stage Renal Disease on Regular Hemodialysis

Efficacy of Ombitasvir/Paritaprevir/Ritonavir plus Ribavirin in Treatment of Chronic Hepatitis C Patients with End Stage Renal Disease on Regular Hemodialysis

Contact Info

Product

Resources

About